D
Daniel R. Gentry
Researcher at GlaxoSmithKline
Publications - 21
Citations - 1364
Daniel R. Gentry is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Staphylococcus aureus & Antibacterial agent. The author has an hindex of 13, co-authored 21 publications receiving 1187 citations.
Papers
More filters
Journal ArticleDOI
Type IIA topoisomerase inhibition by a new class of antibacterial agents.
Benjamin D. Bax,Pan F. Chan,Drake S. Eggleston,Drake S. Eggleston,Andrew P. Fosberry,Daniel R. Gentry,Fabrice Gorrec,Fabrice Gorrec,Ilaria Giordano,Michael M. Hann,Alan Joseph Hennessy,Martin Hibbs,Jianzhong Huang,Emma J. Jones,Jo J. Jones,Kristin K. Brown,Ceri J. Lewis,Earl May,Earl May,Martin R. Saunders,Onkar M. P. Singh,Claus Spitzfaden,Carol Shen,Anthony Shillings,Andrew J. Theobald,Alexandre Wohlkonig,Alexandre Wohlkonig,Neil D. Pearson,Michael N. Gwynn +28 more
TL;DR: This work provides new insights into the mechanism of topoisomerase action and a platform for structure-based drug design of a new class of antibacterial agents against a clinically proven, but conformationally flexible, enzyme class.
Journal ArticleDOI
Isolation and characterization of a sigB deletion mutant of Staphylococcus aureus.
R. O. Nicholas,Tong Li,Damien McDevitt,Andrea Marra,S. Sucoloski,P. L. Demarsh,Daniel R. Gentry +6 more
TL;DR: The sigB gene of Staphylococcus aureus, coding for the alternate sigma factor B, has been deleted by allelic replacement mutagenesis and the mutant grew as well as the parent in vitro, although it was deficient in clumping factor, coagulase, and pigment.
Journal ArticleDOI
Identification, Substrate Specificity, and Inhibition of theStreptococcus pneumoniae β-Ketoacyl-Acyl Carrier Protein Synthase III (FabH)
Sanjay S. Khandekar,Daniel R. Gentry,Glenn S. Van Aller,Patrick Vernon Warren,Hong Xiang,Carol Silverman,Michael L. Doyle,Chambers Pamela Anne,Alex K. Konstantinidis,Martin Brandt,Robert A. Daines,John T. Lonsdale +11 more
TL;DR: The availability of purified and characterized S. pneumoniae FabH will greatly aid in structural studies of this class of essential bacterial enzymes and facilitate the identification of small molecule inhibitors of type II fatty acid synthase with the potential to be novel and potent antibacterial agents active against pathogenic bacteria.
Journal ArticleDOI
Nanomolar Inhibitors of Staphylococcus aureus Methionyl tRNA Synthetase with Potent Antibacterial Activity against Gram-Positive Pathogens
Richard L. Jarvest,John M. Berge,Valerie Berry,Helen F. Boyd,Murray J. B. Brown,John S. Elder,Andrew Keith Forrest,Andrew P. Fosberry,Daniel R. Gentry,Martin Hibbs,Deborah Dee Jaworski,Peter J. O'Hanlon,Andrew J. Pope,Stephen Rittenhouse,Robert J. Sheppard,Courtney Slater-Radosti,Angela Worby +16 more
TL;DR: Optimized compounds show excellent antibacterial activity against staphylococcal and enterococcal pathogens, including strains resistant to clinical antibiotics, and demonstrated in vivo efficacy in an S. aureus rat abscess infection model.
Journal ArticleDOI
Stepwise Exposure of Staphylococcus aureus to Pleuromutilins Is Associated with Stepwise Acquisition of Mutations in rplC and Minimally Affects Susceptibility to Retapamulin
TL;DR: It is likely that target-specific resistance to retapamulin will be slow to emerge due to the need for three mutations for a significant effect on activity and the fitness cost of each mutational step, and mutations in rplC that lead to pleuromutilin resistance have a direct, negative effect on fitness.